WPI Nano-Life Science Institute (Nano-LSI), Kanazawa University, Kanazawa, Japan.
Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Cancer Res. 2024 Jan 2;84(1):56-68. doi: 10.1158/0008-5472.CAN-23-1490.
UNLABELLED: Signaling by TGFβ family cytokines plays a tumor-suppressive role by inducing cell differentiation, while it promotes malignant progression through epithelial-to-mesenchymal transition (EMT). Identification of the mechanisms regulating the switch from tumor suppression to tumor promotion could identify strategies for cancer prevention and treatment. To identify the key genetic alterations that determine the outcome of TGFβ signaling, we used mouse intestinal tumor-derived organoids carrying multiple driver mutations in various combinations to examine the relationship between genotypes and responses to the TGFβ family cytokine activin A. KrasG12D mutation protected organoid cells from activin A-induced growth suppression by inhibiting p21 and p27 expression. Furthermore, Trp53R270H gain-of-function (GOF) mutation together with loss of wild-type Trp53 by loss of heterozygosity (LOH) promoted activin A-induced partial EMT with formation of multiple protrusions on the organoid surface, which was associated with increased metastatic incidence. Histologic analysis confirmed that tumor cells at the protrusions showed loss of apical-basal polarity and glandular structure. RNA sequencing analysis indicated that expression of Hmga2, encoding a cofactor of the SMAD complex that induces EMT transcription factors, was significantly upregulated in organoids with Trp53 GOF/LOH alterations. Importantly, loss of HMGA2 suppressed expression of Twist1 and blocked activin A-induced partial EMT and metastasis in Trp53 GOF/LOH organoids. These results indicate that TP53 GOF/LOH is a key genetic state that primes for TGFβ family-induced partial EMT and malignant progression of colorectal cancer. Activin signaling may be an effective therapeutic target for colorectal cancer harboring TP53 GOF mutations. SIGNIFICANCE: KRAS and TP53 mutations shift activin-mediated signaling to overcome growth inhibition and promote partial EMT, identifying a subset of patients with colorectal cancer that could benefit from inhibition of TGFβ signaling.
未加标签:TGFβ 家族细胞因子的信号传导通过诱导细胞分化发挥肿瘤抑制作用,而通过上皮-间质转化 (EMT) 促进恶性进展。确定调节从肿瘤抑制到肿瘤促进的开关的机制可以确定癌症预防和治疗的策略。为了确定决定 TGFβ 信号转导结果的关键遗传改变,我们使用携带各种组合中的多种驱动突变的小鼠肠肿瘤衍生类器官来检查基因型与 TGFβ 家族细胞因子激活素 A 反应之间的关系。KrasG12D 突变通过抑制 p21 和 p27 的表达来保护类器官细胞免受激活素 A 诱导的生长抑制。此外,Trp53R270H 功能获得 (GOF) 突变与野生型 Trp53 通过杂合性丢失 (LOH) 的丢失一起促进激活素 A 诱导的部分 EMT,在类器官表面形成多个突起,这与增加的转移发生率有关。组织学分析证实,突起处的肿瘤细胞表现出顶端-基底极性和腺体结构的丧失。RNA 测序分析表明,在具有 Trp53 GOF/LOH 改变的类器官中,编码诱导 EMT 转录因子的 SMAD 复合物辅助因子的 Hmga2 的表达显著上调。重要的是,HMGA2 的缺失抑制了 Twist1 的表达,并阻断了 Trp53 GOF/LOH 类器官中激活素 A 诱导的部分 EMT 和转移。这些结果表明,TP53 GOF/LOH 是 TGFβ 家族诱导的部分 EMT 和结直肠癌恶性进展的关键遗传状态。激活素信号可能是携带 TP53 GOF 突变的结直肠癌的有效治疗靶点。
Cancer Res. 2017-12-27
Mol Cancer. 2015-10-24
J Cell Physiol. 2013-4
Int J Mol Sci. 2025-7-9
World J Gastrointest Oncol. 2025-6-15
Int J Mol Med. 2025-1
MedComm (2020). 2024-6-29
Semin Cancer Biol. 2022-11
Int J Oncol. 2019-8-13